Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study.

Margitta Retz,Florian Seseke,Giuseppe Luigi Banna,Ugo De Giorgi,Thomas Powles,Umberto Basso,Raymond S. McDermott,Anna Lladó,Wen-Pin Su,Cristina Ligia Cebotaru,Javier Puente,Álvaro Montesa,Jacques De Grève,Zsuzsanna Kahán,Urbano Anido Herranz,Sabine de Ducla,Julie Pavlova,Simon Fear,Cora N. Sternberg

Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study.

2020

Margitta Retz
Florian Seseke
Giuseppe Luigi Banna
Ugo De Giorgi
Thomas Powles
Umberto Basso
Raymond S. McDermott
Anna Lladó
Wen-Pin Su
Cristina Ligia Cebotaru
Javier Puente
Álvaro Montesa
Jacques De Grève
Zsuzsanna Kahán
Urbano Anido Herranz
Sabine de Ducla
Julie Pavlova
Simon Fear
Cora N. Sternberg

5036Background: Atezo, which targets PD-L1, is an approved therapy for LA/M urothelial carcinoma based on the IMvigor210 and IMvigor211 trials. The single-arm SAUL study (NCT02928406) showed consis...

Keywords:

Urology
Atezolizumab
Urinary system
Pathology
in patient
locally advanced
Medicine
Carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations